Envestnet Asset Management Inc. Purchases 2,811 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Envestnet Asset Management Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,727 shares of the company's stock after buying an additional 2,811 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.33% of Medpace worth $33,797,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of MEDP. Investidor Profissional Gestao de Recursos Ltda. acquired a new stake in shares of Medpace in the fourth quarter valued at $240,000. Grantham Mayo Van Otterloo & Co. LLC acquired a new position in Medpace in the fourth quarter valued at approximately $5,712,000. Aviva PLC boosted its stake in Medpace by 2.7% in the fourth quarter. Aviva PLC now owns 1,833 shares of the company's stock valued at $609,000 after acquiring an additional 48 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Medpace during the 4th quarter valued at $273,000. Finally, Grant Private Wealth Management Inc bought a new stake in Medpace in the fourth quarter valued at about $279,000. Institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MEDP shares. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and reduced their target price for the stock from $370.00 to $328.00 in a report on Monday. Truist Financial dropped their target price on shares of Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Mizuho lowered their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Ten equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $357.50.

Medpace Stock Performance

Shares of Medpace stock traded down $2.82 during midday trading on Thursday, hitting $293.68. 288,386 shares of the company traded hands, compared to its average volume of 323,423. The stock has a market cap of $8.88 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 3.81 and a beta of 1.46. The firm's fifty day moving average price is $320.31 and its 200-day moving average price is $333.83. Medpace Holdings, Inc. has a 12 month low of $272.00 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.